Prediction of phospholipidosis-inducing potential of drugs by in vitro biochemical and physicochemical assays followed by multivariate analysis

Toxicology in Vitro

Volumn 24, Issue 2, 2010, Pages 661-668

  Kuroda, Yukihiro ^a   Saito, Madoka ^a  

^a MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

Author keywords

Cationic amphiphilic drug; Drug induced phospholipidosis; Partition coefficient; Phospholipase A2; Phospholipid vesicle; pKa; Principal component analysis; Rat liver microsome

Indexed keywords

AMIODARONE; CHLORAMPHENICOL; CHLOROQUINE; CHLORPROMAZINE; DISOPYRAMIDE; IMIPRAMINE; LIDOCAINE; MICROSOME ENZYME; PHOSPHOLIPID; PROPRANOLOL;

ACCURACY; ANIMAL CELL; ARTICLE; ASSAY; BIOCHEMISTRY; CONTROLLED STUDY; DISSOCIATION CONSTANT; ENZYMATIC DEGRADATION; IN VITRO STUDY; LIPIDOSIS; LIVER MICROSOME; MALE; MULTIVARIATE ANALYSIS; NONHUMAN; PHYSICAL CHEMISTRY; PREDICTION; PRINCIPAL COMPONENT ANALYSIS; RAT;

CATIONS; DIPHENYLHEXATRIENE; FLUORESCENT DYES; HUMANS; LIPIDOSES; MICROSOMES; MULTIVARIATE ANALYSIS; PHARMACEUTICAL PREPARATIONS; PHOSPHOLIPASES A2; PRINCIPAL COMPONENT ANALYSIS; PROTEIN BINDING;

RATTUS;

EID: 76549133762     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2009.09.018     Document Type: Article

References (39)

1. Baronas E.T., Lee J., Alden C., and Hsieh F.Y. Biomarkers to monitor drug-induced phospholipidosis. Toxicology and Applied Pharmacology 218 (2007) 72-78
2. Casartelli A., Bonato M., Cristofori P., Crivellente F., Dal Negro G., Massoto I., Mutinelli C., Valko K., and Bonfante V. A cell-based approach for the early assessment of the phospholipidogenic potential in pharmaceutical research and drug development. Cell Biology and Toxicology 19 (2003) 161-176
3. Colombo M.I., and Bertini F. Properties of binding sites for chloroquine in liver lysosomal membranes. Journal of Cellular. Physiology 137 (1988) 598-602
4. de Duve C., De Barsy T., Poole B., Trouet A., Turkens P., and Van Hoof F. Commentary. Lysosomotropic agents. Biochemical Pharmacology 23 (1974) 2495-2531
5. 2. Journal of Biological Chemistry 269 (1994) 13057-13060
6. 14C choline in the rat lung phospholipids. Lipids 21 (1986) 230-234
7. 2. Biochemical Pharmacology 36 (1987) 1063-1067
8. Hasegawa M., Takenaka S., Kuwamura M., Yamate J., and Tsuyama S. Urinary metabolic fingerprinting for amiodarone-induced phospholipidosis in rats using FT-ICR MS. Experimental and Toxicologic Pathology 59 (2007) 115-120
9. 2 and phospholipidosis. Molecular and Cellular Biology 26 (2006) 6139-6148
10. Hirode M., Ono A., Miyagishima T., Nagao T., Ohno T., and Urushidani T. Gene expression profiling in rat liver treated with compounds inducing phospholipidosis. Toxicology and Applied Pharmacology 229 (2008) 290-299
11. Hostetler K.Y., and Matsuzawa Y. Studies on the mechanism of drug-induced lipidosis. Cationic amphiphilic drug inhibition of lysosomal phospholipases A and C. Biochemical Pharmacology 30 (1981) 1121-1126
12. Hutchinson T.H., Mahshid Y., Jönsson R., Björklund C., and Kenne K. Proteomic analysis of phospholipidosis in citalopram treated U937 cells - support for the cholesterol biosynthesis hypothesis. Toxicology in Vitro 22 (2008) 1198-1204
13. Joshi U.M., Prasada R.S., Kodavanti B.C., Dwyer T.M., and Mehendale H.M. Types of interaction of amphiphilic drugs with phospholipid vesicles. Journal of Pharmacological and Experimental Therapeutics 246 (1988) 150-157
14. Joshi U.M., Rao P., Kodavanti P.R.S., Lockard V.G., and Mehendale H.M. Fluorescence studies on binding of amphiphilic drugs to isolated lamellar bodies: relevance to phospholipidosis. Biochimica et Biophysica Acta 1004 (1989) 309-320
15. Kaiser R.D., and London E. Location of diphenylhexatriene (DPH) and its derivatives within membranes: comparison of different fluorescence quenching analyses of membrane depth. Biochemistry 37 (1998) 8180-8190
16. Kasahara T., Tomita K., Murano H., Harada T., Tsubakimoto K., Ogihara T., Ohnishi S., and Kakinuma C. Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential. Toxicological Sciences 90 (2006) 133-141
17. Kodavanti U.P., and Mehendale H.M. Cationic amphiphilic drugs and phospholipid storage disorder. Pharmacological Reviews 42 (1990) 327-354
18. Kubo M., and Hostetler K.Y. Mechanism of cationic amphiphilic drug inhibition of purified lysosomal phospholipase A1. Biochemistry 24 (1985) 6515-6520
19. Lullumann H., and Wehling M. The binding of drugs to different polar lipids in vitro. Biochemical Pharmacology 28 (1979) 3409-3415
20. Lullumann H., Lullumann-Rauch R., and Wassermann O. Lipidosis induced by amphiphilic cationic drugs. Biochemical Pharmacology 27 (1978) 1103-1108
21. Ma J.Y.C., Ma J.K.H., and Weber K.C. Fluorescence studies of the binding of amphiphilic amines with phospholipids. Journal of Lipid Research 26 (1985) 735-744
22. Matsuzawa Y., and Hostetler K.Y. Inhibition of lysosomal phospholipase A and phospholipase C by chloroquine and 4,4′-bis(diethylaminoethoxy) alpha, beta-diethyldiphenylethane. Journal of Biological Chemistry 255 (1980) 5190-5194
23. 3 H glycerol into the phospholipids of rat liver lysosomes and other subcellular fractions, in vivo. Biochimica et Biophysica Acta 620 (1980) 592-602
24. Miles P.R., Bowman L., Tucker J., Reasor M.J., and Wright J.R. Alterations in rat alveolar surfactant phospholipids and proteins induced by administration of chlorphentermine. Biochimica et Biophysica Acta 877 (1986) 167-178
25. Morelli J.K., Buehrle M., Pognan F., Barone L.R., Fieles W., and Ciaccio P.J. Validation of an in vitro screen for phospholipidosis using a high-content biology platform. Cell Biology and Toxicology 22 (2006) 15-27
26. Mortuza G.B., Neville A., Delaney J., Waterfield C.J., and Camilleri P. Characterisation of a potential biomarker of phospholipidosis from amiodarone-treated rats. Biochimica et Biophysica Acta 1631 (2003) 136-146
27. Ohmiya Y., and Mehendale H.M. Pulmonary metabolism of imipramine in the rat and rabbit. Comparison with hepatic metabolism. Pharmacology 22 (1981) 172-182
28. Ohmiya Y., and Mehendale H.M. Metabolism of chlorpromazine by pulmonary microsomal enzymes in the rat and rabbit. Biochemical Pharmacology 31 (1982) 157-162
29. Ohmiya Y., and Mehendale H.M. Species differences in pulmonary N-oxidation of chlorpromazine and imipramine. Pharmacology 28 (1984) 289-295
30. a and CLog P to predict phospholipidosis-inducing potential: a case study with structurally related piperazines. Experimental and Toxicologic Pathology 55 (2004) 347-355
31. Reasor M.J., McCloud C.M., Beard T.L., Ebert D.C., Kasew S., Gardner M.F., Aldern K.A., and Hostetler K.Y. Comparative evaluation of amiodarone-induced phospholipidosis and drug accumulation in Fischer-344 and Sprague-Dawley rats. Toxicology 106 (1996) 139-147
32. Repáková J., Čapková P., Holopainen J.M., and Vattulainen I. Distribution, orientation, and dynamics of DPH probes in DPPC bilayer. The Journal of Physical Chemistry B 108 (2004) 13438-13448
33. 1-AG in human serum. Biochemical Pharmacology 34 (1985) 821-829
34. Taillardat-Bertschinger A., Martinet C.A., Carrupt P.A., Reist M., Caron G., Fruttero R., and Testa B. Molecular factors influencing retention on immobilized artificial membranes (IAM) compared to partitioning in liposomes and n-octanol. Pharmaceutical. Research 55 (2004) 347-355
35. Tolonen A., Turpeinen M., and Pelkonen O. Liquid chromatography-mass spectrometry in in vitro drug metabolite screening. Drug Discovery Today 14 (2008) 120-133
36. Tomizawa K., Sugano K., Yamada H., and Horii I. Physicochemical and cell-based approach for early screening of phospholipidosis-inducing potential. The Journal of Toxicological Sciences 31 (2006) 315-324
37. Valco K., Du C.M., Bevan C.D., Reynolds D.P., and Abraham M.H. Rapid-gradient HPLC method for measuring drug interactions with immobilized artificial membrane: comparison with other lipophilicity measures. Journal of Pharmaceutical Sciences 89 (2000) 1085-1096
38. Vejux A., Malvitte L., and Lizard G. Side effects of oxysterols: cytotoxicity, oxidation, inflammation, and phospholipidosis. Brazilian Journal of Medical and Biological Research 41 (2008) 545-556
39. Vitocič P., Alakoskela J., and Kinnunen K.J. Assessment of drug-lipid complex formation by a high-throughput Langmuir-balance and correlation to phospholipidosis. Journal of Medicinal Chemistry 51 (2008) 1842-1848